Summary
The pulmonary system is modified in various ways over time and it is particularly vulnerable to environmental insults. Of particular interest are the implications of aging for therapy of respiratory illnesses. The changes in pulmonary structure and function due simply to aging, and changes due to diseases, should be distinguished from each other.
The great reserve function of the lung permits reasonable physical capacity in healthy individuals despite aging changes. In principle, loss of function equivalent to more than one lung is necessary to impair aerobic capacity at any age.
Elderly people are subject to the same respiratory diseases as younger adults but may manifest them differently. They may present in atypical ways such as in bacterial pneumonia, tuberculosis, and asthma, all modified by anatomical alterations or deterioration of immunological defence mechanisms.
Accumulation of toxic substances over time such as cigarette smoke or environmental pollutants may give rise to chronic bronchitis, emphysema, bronchogenic carcinoma and interstitial lung disease.
Changes in the number or function of airway receptors modulate responses to bronchodilator drugs. Chronic inflammation of the bronchial wall has blurred the distinction between traditional asthma and chronic bronchitis and emphysema, and similar drug therapy can be useful for all.
Adverse reactions to respiratory drugs such as theophylline, oral corticosteroids, and isoniazid increase with age. As more data accumulate, drug therapy of respiratory diseases in older patients will become more effective and safer.
Similar content being viewed by others
References
American Thoracic Society. Treatment of tuberculosis and tuberculous infection in adults and children. American Review of Respiratory Disease 134: 335–366, 1986
American Thoracic Society. Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. American Review of Respiratory Disease 140: 1494–1497, 1989
Auerbach O, Stout AP, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. New England Journal of Medicine 265: 253–267, 1961
Barnes PJ. A new approach to the treatment of asthma. New England Journal of Medicine 321: 1517–1527, 1989
Barros M, Rees PJ. Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction. Respiratory Medicine 84: 371–375, 1990
Berry RB, Shinto RA, Wong FH, Despars JA, Light RW. Nebulizer vs spacer for bronchodilator delivery in patients hospitalized for acute exacerbation of COPD. Chest 96: 1241–1246, 1989
Braun SR, McKenzie WN, Copeland C, Knight L, Ellersieck M. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Archives of Internal Medicine 149: 544–547, 1989
Bukowsky M, Nakatsu K, Munt PW. Theophylline reassessed. Annals of Internal Medicine 101: 63–73, 1984
Busse WW. The role of inflammation in asthma: a new focus. Journal of Respiratory Disease 10: 72–80, 1989
Centers for Disease Control. A strategic plan for the elimination of tuberculosis in the United States. Morbidity and Mortality Weekly Report 38: 269–272, 1989
Centers for Disease Control. Prevention and control of influenza. Morbidity and Mortality Weekly Report 41: 1–17, 1992
Chapman KR. Anticholinergic bronchodilators for adult obstructive airways disease. American Journal of Medicine 91(Suppl. 4A): 13S–16S, 1991
Check WA, Kaliner MA. Pharmacology and pharmacokinetics of topical corticosteroid derivatives used for asthma therapy. American Review of Respiratory Disease 141: S44–S51, 1990
Crown JPA, Chahmian AP, Jaffrey IS, et al. Predictors of 5-year survival and curability in small cell lung cancer. Cancer 66: 382–386, 1990
Dutoit JI, Salome CM, Woolcock AJ. Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but theophylline does not. American Review of Respiratory Disease 138: 1174–1178, 1987
Edson RS, Terrell CI. The aminoglycosides. Mayo Clinic Proceedings 66: 1158–1164, 1991
Erzurum SC, Leff JA, Cochran JE, Ackerson LM, Szefler SJ, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study. Annals of Internal Medicine 114: 353–360, 1991
Ferguson GT, Cherniak RM. Management of chronic obstructive pulmonary disease. New England Journal of Medicine 328: 1017–1022, 1993
Fox RA. Treatment recommendations for respiratory tract infections associated with aging. Drugs & Aging 3: 40–48, 1993
Geokas MC, Lakatta EG, Makinodan T, Timiras PS. The aging process. Annals of Internal Medicine 113: 455–466, 1990
Gervais A, Begin P. Bronchodilation with a metered-dose inhaler plus an extension, using tidal breathing vs jet nebulizer. Chest 92: 822–824, 1987
Gross NJ. The influence of anticholinergic agents on treatment for bronchitis and emphysema. American Journal of Medicine 91(Suppl. 4A): 115–125, 1991
Haas H, Morris JF, Samson S. Effect of oral penicillin on pneumococcal carriage in elderly men with chronic bronchitis. Clinical Therapeutics 8: 301–308, 1986
Hayden FG, Monto AS. Oral rimantidine hydrochloride therapy of influenza A H3N2 subtype infection in adults. Antimicrobial Agents Chemotherapy 29: 339–341, 1986
Heijboer H, Buller HR, Lensing AWR, Turpie AGG, Colly LP, et al. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep vein thrombosis in symptomatic outpatients. New England Journal of Medicine 329: 1365–1369, 1993
Hendeles L, Weinberger M. Theophylline: A ‘state of the art’ review. Pharmacotherapy 3: 2–44, 1983
Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. New England Journal of Medicine 322: 1260–1264, 1990
Kim WD, Eidelman DH, Izquierdo JL, Ghezzo H, Saetta MP, et al. Centrilobular and panlobular emphysema in smokers. American Review of Respiratory Disease 144: 1385–1390, 1991
Karpel JP. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 99: 871–876, 1991
Kelley J. Cytokines of the lung. American Review of Respiratory Disease 141: 765–788, 1990
Kronenberg RS, Drage CW. Attenuation of the ventilatory and heart rate responses to hypoxia and hypercapnia with aging in normal men. Journal of Clinical Investigation 52: 1812–1829, 1973
LeDoux EJ, Morris JF, Temple WP, Duncan C. Standard and double dose of ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Chest 95: 1013–1016, 1989
Martin RJ, Pak J. Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease. American Review of Respiratory Disease 145: 540–544, 1992
Mestitz H, Copland JM, McDonald CF. Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction. Chest 96: 1237–1240, 1989
Miller A (Ed). Spirometry and maximum expiratory flow-volume curves. Pulmonary function tests in clinical and occupational lung disease 1986, pp. 15–46, Grune & Stratton, New York, 1986
Morris JF. Pulmonary Diseases, In Cassel et al. (Eds) Geriatric Medicine, 2nd ed., pp. 373–374, Springer-Verlag, New York, 1990
Morris JF, Duncan CA, Temple WP. Comparison of nebulized with metered-dose inhaled metaproterenol in stable COPD. American Review of Respiratory Disease 143: A447, 1991a
Morris JF, Koski A, Temple WP, Claremont A, Thomas DR. Fifteen-year interval spirometric evaluation of the Oregon predictive equations. Chest 93: 123–127, 1988
Morris JF, Krishnamurthy S, Antonovic R, Duncan C, Turner FE, et al. Technetium 99m monoclonal antibody fragment (Fb) scintigraphy in the evaluation of small cell lung cancer: a preliminary report. Nuclear Medicine and Biology — International Journal of Radiation Applications and Instrumentation Part B 19: 613–620, 1991b
Morris JF, Temple WP. Spirometric ‘lung age’ estimation for motivating smoking cessation. Preventive Medicine 14: 655–662, 1985
Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, et al. Methotrexate in the treatment of corticosteroid-dependent asthma. A double-bind crossover study. New England Journal of Medicine 318: 603–607, 1988
Murciano D, Aubier M, Lecocguic Y, Pariente R. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. New England Journal of Medicine 311: 349–353, 1984
Murray JF. Defense Mechanisms in the Normal Lung, 2nd Edition, pp. 25–28, 313–337, 339–360, WB Saunders Company, Sidney, 1986
Nagai A, Yamawaki I, Takizawa T, Thrulbeck WM. Alveolar attachments in emphysema of human lung. American Review of Respiratory Disease 144: 888–891, 1991
National Asthma Guidelines for the Diagnosis and Management of Asthma. Expert panel report. National Institutes of Health Pub. No. 91-3042, 1991
Newhouse M, Sanchis J, Bienstock J. Lung defense mechanisms. New England Journal of Medicine 295: 990–995, 1976
Nielsen-Kudsk F, Magnussen T, Jakobsen N. Pharmacokinetics of theophylline in ten elderly patients. Acta Pharmacologica Toxica 42: 226–234, 1978
Oregon Thoracic Society. COPD manual for physicians, American Lung Association, New York, 1966
Orme IM. Aging and immunity to tuberculosis: increased susceptibility of old reflects a decreased capacity to generate T lymphocytes. Journal of Immunology 138: 4414–4418, 1987
Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 44: 498–529, 1992
Patriarca PA, Arden NH, Kaplan JP, Goodman RA. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Annals of Internal Medicine 107: 732–740, 1987
Phair JP, Kauffman CA, Bjornson A, Gallagher J, Adams L, et al. Host defenses in the aged: evaluation of components of the inflammatory and immune responses. Journal of Infectious Diseases 138: 67–73, 1978
Pollack ML, Foster C, Knapp D, Rod JL, Schmidt DH. Effect of age and training on aerobic capacity and body composition of master athletes. Journal of Applied Physiology 62: 725–731, 1987
Rogers R, Owens G, Pennock B. The pendulum swings toward rational use of theophylline. Chest 87: 280–282, 1985
Roghmann KJ, Tabloski PA, Bentley DW, Schiffman G. Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment. Journal of Gerontology 42: 265–270, 1987
Sanders WE, Morris JF, Alessi P, Makris AT, McCloskey RV, et al. Oral ofloxacin for the treatment of acute bacterial pneumonia. Use of a nontraditional protocol to compare experimental therapy with ‘usual care’ in a multicenter clinical trial. American Journal of Medicine 91: 261–266, 1991
Schocken DD, Roth GS. Reduced β-adrenergic receptor concentrations in ageing man. Nature 267: 856–858, 1977
Scordamaglia A, Ciprandi G, Indiveri F, Canonica GW. The effect of aging on host defences. Implications for therapy. Drugs & Aging 1: 303–316, 1991
Sears MR, Taylor DR, Print CG, Lake DC, Li Q, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336: 1391–1396, 1990
Shannon M, Lovejoy Jr FH. The influence of age vs peak serum concentration on life-threatening events after chronic theophylline intoxication. Archives of Internal Medicine 150: 2045–2048, 1990
Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Annals of Internal Medicine 108: 653–657, 1988
Snider Jr DE, Roper WL. The new tuberculosis. New England Journal of Medicine 326: 703–705, 1992
Sontag SJ, O’Connell S, Khandelwal S, Miller T, Nemchausky B, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 99: 613–620, 1990
Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, et al. The use of β-agonists and the risk of death and near death from asthma. New England Journal of Medicine 326: 501–506, 1992
Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. New England Journal of Medicine 312: 1483–1487, 1985
Thurlbeck WM. Growth, aging, and adaptation. In Murray & Nadel (Eds), Textbook of Respiratory Medicine, pp. 43–46, WB Saunders, Philadelphia, 1988
Tobin MJ, Jenouri G, Danta I, Kim C, Watson H. Response to bronchodilator drug administration by a new reservoir delivery system and a review of other auxiliary delivery systems. American Review of Respiratory Disease 126: 670–675, 1982
Tockman MS. The effects of age on the lung. In The Merck manual of geriatrics, pp. 423–459, Merck Sharp & Dohme Laboratories, Rahway, NJ, 1990
Toogood JH. High-dose inhaled steroid therapy for asthma. Journal of Allergy and Clinical Immunology 83: 528–536, 1989
Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Journal of the American Medical Association 266: 3133–3138, 1991
Ullah MI, Newman GB, Saunders KB. Influence of age on response to ipratropium bromide and salbutamol in asthma. Thorax 36: 523–529, 1981
US Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A Report of the Surgeon General, Washington, DC, 1989, U.S. Government Printing Office, publication No. 89-8411
Van Schayck CD, Dompeling E, Van Herwaarden CLA, Folgering H, Verbeek ALM, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. British Medical Journal 303: 1426–1430, 1991
Wassermann K, Whipp BJ. Exercise physiology in health and disease. American Review of Respiratory Disease 141: 219–249, 1975
Woodring JH, Vandiviere HM, Fried AM, Dillon ML, Williams TD, et al. Update: the radiographic features of pulmonary tuberculosis. American Journal of Radiology 146: 497–506, 1986
Wynne, JW. Steroid therapy for pneumonitis induced in rabbits by aspiration of foodstuff. Anesthesiology 51: 11–19, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morris, J.F. Physiological Changes Due to Age. Drugs & Aging 4, 207–220 (1994). https://doi.org/10.2165/00002512-199404030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199404030-00004